These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 33202035)

  • 41. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR Screens in Toxicology Research: An Overview.
    Sobh A; Russo M; Vulpe CD
    Curr Protoc; 2021 May; 1(5):e136. PubMed ID: 34043288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRISPR technology for immuno-oncology applications.
    Wang J; Balan V; Marincola F
    Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
    Klann TS; Black JB; Chellappan M; Safi A; Song L; Hilton IB; Crawford GE; Reddy TE; Gersbach CA
    Nat Biotechnol; 2017 Jun; 35(6):561-568. PubMed ID: 28369033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes.
    Soyars CL; Peterson BA; Burr CA; Nimchuk ZL
    Plant Cell Physiol; 2018 Aug; 59(8):1608-1620. PubMed ID: 29912402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR-Cas9 System: Opportunities and Concerns.
    Vasiliou SK; Diamandis EP; Church GM; Greely HT; Baylis F; Thompson C; Schmitt-Ulms G
    Clin Chem; 2016 Oct; 62(10):1304-11. PubMed ID: 27551006
    [No Abstract]   [Full Text] [Related]  

  • 48. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
    Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
    J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
    Tapscott T; Guarnieri MT; Henard CA
    Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Directed Evolution of CRISPR-Cas9 Base Editors.
    Winter J; Perez-Pinera P
    Trends Biotechnol; 2019 Nov; 37(11):1151-1153. PubMed ID: 31623959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Biology and Application Areas of CRISPR Technologies.
    Adli M
    J Mol Biol; 2019 Jan; 431(1):1-2. PubMed ID: 30447221
    [No Abstract]   [Full Text] [Related]  

  • 53. Advancements in CRISPR/Cas9 technology-Focusing on cancer therapeutics and beyond.
    Mirza Z; Karim S
    Semin Cell Dev Biol; 2019 Dec; 96():13-21. PubMed ID: 31150758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploring retinal degenerative diseases through CRISPR-based screening.
    Li R; Yang F; Chu B; Kong D; Hu J; Qian H
    Mol Biol Rep; 2024 Sep; 51(1):1029. PubMed ID: 39349793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.
    Wang Y; Wang S; Chen W; Song L; Zhang Y; Shen Z; Yu F; Li M; Ji Q
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217854
    [No Abstract]   [Full Text] [Related]  

  • 56. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Off- and on-target effects of genome editing in mouse embryos.
    Ayabe S; Nakashima K; Yoshiki A
    J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology.
    Xu X; Qi LS
    J Mol Biol; 2019 Jan; 431(1):34-47. PubMed ID: 29958882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRISPR-Cas9 therapies in experimental mouse models of cancer.
    Estêvão D; Rios Costa N; da Costa RG; Medeiros R
    Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.